Compare CTLP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTLP | AKBA |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 798.9M | 729.1M |
| IPO Year | N/A | 2014 |
| Metric | CTLP | AKBA |
|---|---|---|
| Price | $10.84 | $1.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 856.1K | ★ 3.1M |
| Earning Date | 02-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 371.48 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $312,565,000.00 | $225,071,000.00 |
| Revenue This Year | $16.11 | $52.38 |
| Revenue Next Year | $14.37 | $22.45 |
| P/E Ratio | $13.55 | ★ N/A |
| Revenue Growth | 12.94 | ★ 32.49 |
| 52 Week Low | $7.01 | $1.31 |
| 52 Week High | $11.36 | $4.08 |
| Indicator | CTLP | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 32.17 |
| Support Level | $10.68 | $1.33 |
| Resistance Level | $10.90 | $1.41 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 82.89 | 11.53 |
Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.